Sepsis is a common and frequently fatal condition and there is an urgent need for new therapies that will further reduce sepsis-induced mortality. Macrophage migration inhibitory (MIF) factor is important in the regulation of innate and adaptive immunity and is believed to play a key regulatory role in sepsis and autoimmune disease. As MIF deficiency or immunoneutralization protects mice or rats from fatal endotoxic shock or other inflammatory diseases, we examined whether DNA vaccination against this molecule would also be protective. DNA vaccines can stimulate both humoral and cellular immunity simultaneously and have been shown to be effective against a variety of pathogens or cytokinedriven pathologies. Mice were immunized with a MIF/tetanus toxin (TTX) DNA vaccine and sepsis was then induced by lipopolysaccharide or cecal ligation and puncture. The MIF/ TTX DNA-vaccinated mice were protected from the lethal effect of sepsis compared with control-vaccinated mice in both models. Compared with the control-vaccinated mice, the MIF/TTX DNA-vaccinated mice also showed significantly lower serum tumor necrosis factor (TNF)-a protein levels and reduced mRNA expression of TNF-a, interleukin (IL)-1b, IL-6, macrophage inflammatory protein-2 and Toll-like receptor-4 in the lungs. Thus, the MIF/TTX DNA vaccine may be useful for the prophylaxis of septic shock.
Introduction
Macrophage migration inhibitory factor (MIF) is a cytokine that plays a pivotal role in the regulation of innate and adaptive immunity. 1 It appears to participate in multiple autoimmune and inflammatory states, including sepsis, rheumatoid arthritis, acute respiratory distress syndrome (ARDS), glomerulonephritis and enterocolitis. 2 MIF immunoneutralization and MIF gene deficiencies are associated with protection from endotoxic shock and lethality; abrogating MIF activity also significantly reduces inflammation in several experimental models of autoimmune disease. 3 MIF, unlike other cytokines such as tumor necrosis factor (TNF)-a, has a widespread distribution in tissues and is stored in large amounts in immune cells or fibroblasts. 4 This suggests that MIF may be a high-level regulator of immune and inflammatory events that are induced by other factors such as endotoxin and cytokines. 1 Supporting this is that endogenous MIF is necessary for the Toll-like receptor (TLR)-4 expression that is needed for macrophages to respond to endotoxin. 5 Moreover, immunoneutralization of MIF inhibits the elevation of serum levels of interleukin (IL)-6 and TNF-a in sepsis. 3 These observations suggest that endogenous MIF is important in regulating cellular responses against endotoxin.
Monoclonal antibodies (mAbs) against MIF have been shown to attenuate inflammation in animal models of sepsis 3 and thus it has been speculated that this approach may also be useful for the treatment of sepsis in humans. However, this approach suffers from a number of limitations. First, massive amounts of humanized or heterogeneous Abs have to be injected, which could generate transient but undesirable local and systemic reactions. Second, the protective effects of each Ab infusion is of short duration because of the lack of immune B-cell memory, which necessitates frequent injections of the Abs. 6 We speculated that this therapeutic approach could be improved by active immunization with a therapeutic vaccine that elicits autoantibodies against MIF. In our previous study, we developed a novel DNA vaccine that generates endogenous anti-MIF Abs. 7 This was achieved by constructing the MIF/tetanus toxin (TTX) DNA vaccine, which encodes a variant of murine MIF (mMIF) in which the second loop is replaced by a promiscuous helper T (T H )-cell epitope from TTX. The ability of this vaccine to attenuate inflammation in sepsis was tested here in two different murine models of sepsis.
Results
Vaccination with MIF/TTX DNA protects mice from lethal endotoxemia induced by LPS or CLP Endotoxic shock induced by bacterial lipopolysaccharide (LPS) administration can be fatal, and administration of an antibody against MIF prevents it. 3 We examined whether the autoantibody induced by the MIF/TTX DNA vaccine could also decrease LPS-induced mortality. Thus, 6-7 weeks after vaccination, the mice were challenged with a lethal amount of LPS (15 mg kg Although LPS-induced endotoxemia is useful for investigating the complex cytokine cascades involved in sepsis, more clinically relevant animal models are necessary to explore prophylactic approaches that will combat sepsis. One well-known and standardized animal model of sepsis is induced by cecal ligation and puncture (CLP). 8, 9 In this model, 45% of the pCAGGSvaccinated mice had died by the third day after CLP (Figure 1b) . In contrast, only about 10% of the MIF/TTX DNA-vaccinated mice died after CLP. This difference was statistically significant (Po0.05).
MIF/TTX DNA vaccination suppresses the LPS/CLPinduced elevation of serum proinflammatory cytokine levels
We reported previously that the MIF/TTX DNA vaccine induces a polyclonal Ab response that recognizes native MIF and competes with a MIF-specific mAb for binding to native mMIF protein. 7 In this study, we confirmed that MIF/TTX DNA-vaccinated mice had significantly higher serum anti-MIF Ab titers than pCAGGS-vaccinated mice 6 weeks after vaccination (Figure 2a , Po0.05). We also presented the serum MIF levels at this time point. The serum concentrations of MIF were significantly lower in MIF/TTX group than in control group (Figure 2b , Po0.01), which was correlated with the elevation of serum anti-MIF autoantibody that competes with a MIF-specific mAb for binding to MIF antigen.
We tested whether the MIF/TTX DNA vaccination also suppressed the enhancement of serum levels of proinflammatory cytokines, that is, TNF-a, IL-1b, IL-6, macrophage inflammatory protein-2 (MIP)-2 and MIF, in the septic animals, as pre-administration of polyclonal anti-MIF Ab effectively suppresses the elevation of systemic TNF-a in sepsis models. 3 As shown in Figure 3 , pCAGGS-vaccinated mice had elevated higher serum TNF-a, IL-1b, IL-6, MIP-2 and MIF levels after LPS injection. In MIF/TTX DNA-vaccinated mice, significant suppression of this elevation was seen in TNF-a at 2 h after challenge (Figure 3a , Po0.05). Similarly, pCAGGSvaccinated mice had elevated serum TNF-a, IL-1b, IL-6, MIP-2 and MIF levels after CLP challenge. In MIF/TTX DNA-vaccinated mice, significant suppression of this elevation was seen in MIF at 2 h after challenge (Figure 4e , Po0.05). Other proinflammatory cytokines such as TNF-a or IL-6 also tended to be suppressed in MIF/TTX DNA-vaccinated mice, although the differences were not significant.
Effect of MIF/TTX DNA vaccination on the lung mRNA levels of TNF-a, IL-1b, IL-6, MIP-2 and TLR-4 after LPS or CLP challenge
We also examined the mRNA expression of proinflammatory cytokines that may participate in sepsis and could be influenced by endogenous MIF, namely, TNF-a, IL-1b, IL-6 and MIP-2. For this, we killed pCAGGS-or MIF/TTX DNA-vaccinated mice at 2, 6, 12 and 24 h after challenge with LPS or CLP and subjected their lung mRNAs to quantitative real-time PCR. After LPS challenge, TNF-a mRNA peaked at 6 h in pCAGGSvaccinated mice. TNF-a mRNA levels were significantly lower in the MIF/TTX DNA-vaccinated group than in the pCAGGS-vaccinated group at the 6, 12 and 24 h time points (Po0.001, Po0.01 and Po0.01, respectively; Figure 5a ). IL-1b mRNA levels, which peaked at 12 h in pCAGGS-vaccinated mice, were significantly lower in the MIF/TTX DNA-vaccinated group than in the pCAGGS-vaccinated group at the 12 and 24 h time points (Po0.001 and Po0.01, respectively; Figure 5b ). MIF/TTX DNA vaccination and sepsis S Tohyama et al IL-6 mRNA levels, which peaked at 12 h in pCAGGSvaccinated mice, were significantly lower in the MIF/ TTX DNA-vaccinated group than in the pCAGGSvaccinated group at the 6, 12 and 24 h time points (Po0.01, Po0.001 and Po0.001, respectively; Figure 5c ). MIP-2 mRNA levels, which peaked at 6 h in pCAGGSvaccinated mice, were significantly lower in the MIF/ TTX DNA-vaccinated group than in the pCAGGSvaccinated group at the 2, 6 and 12 h time points (Po0.05, Po0.001 and Po0.01, respectively; Figure 5d ). MIF mRNA levels, which peaked at 12 h in pCAGGSvaccinated mice, were significantly lower in the MIF/ TTX DNA-vaccinated group than in the pCAGGSvaccinated group at 24 h (Po0.01; Figure 5e ). After CLP challenge, TNF-a mRNA peaked at 6-12 h in pCAGGS-vaccinated mice. TNF-a mRNA levels were significantly lower in the MIF/TTX DNA-vaccinated group than in the pCAGGS-vaccinated group at the 6, 12 and 24 h time points (Po0.001, Po0.001 and Po0.01, respectively; Figure 6a ). IL-1b mRNA levels, which peaked at 24 h in pCAGGS-vaccinated mice, were significantly lower in the MIF/TTX DNA-vaccinated group than in the pCAGGS-vaccinated group at 24 h (Po0.001; Figure 6b ). IL-6 mRNA levels, which peaked at 6 h in pCAGGS-vaccinated mice, were significantly lower in the MIF/TTX DNA-vaccinated group than in the pCAGGS-vaccinated group at the 6 and 12 h time points (Po0.001 and Po0.01, respectively; Figure 6c ). MIF/TTX DNA vaccination and sepsis S Tohyama et al MIP-2 mRNA levels, which peaked at 12-24 h in pCAGGS-vaccinated mice, were significantly lower in the MIF/TTX DNA-vaccinated group than in the pCAGGS-vaccinated group at 24 h (Po0.01; Figure 5d ). MIF mRNA levels, which showed elevation at 6-24 h in pCAGGS-vaccinated mice, were not significantly different between MIF/TTX DNA-vaccinated group and pCAGGS-vaccinated group at all time points. Thus, MIF/TTX DNA vaccination suppresses the mRNA upregulation of the proinflammatory cytokines TNF-a, IL-1b, IL-6 and MIP-2 in the lung tissues after sepsis is induced. Finally, we measured the levels of TLR-4 mRNA in the lung tissues, which were upregulated by both LPS and CLP challenges. After LPS challenge, TLR-4 mRNA peaked at 6 h in pCAGGS-vaccinated mice. TLR-4 mRNA levels were significantly lower in the MIF/TTX DNA-vaccinated group than in the pCAGGSvaccinated group at the 6 and 24 h time points (Po0.001 and Po0.01, respectively; Figure 5f ). After CLP challenge, TLR-4 mRNA peaked at 6 h in pCAGGS-vaccinated mice. TLR-4 mRNA levels were significantly lower in the MIF/TTX DNA-vaccinated group than in the pCAGGS-vaccinated group at 6 h (Po0.05; Figure 5f ).
Vaccination with MIF/TTX DNA suppresses acute lung injury
Sepsis induces multiple organ failure, including acute lung injury. Therefore, we examined the lung tissues of the MIF/TTX DNA-or pCAGGS-vaccinated mice in both the LPS and CLP models. Histopathological analysis revealed that the lung tissues of MIF/TTX DNAvaccinated mice were relatively healthy at 12 h after LPS or CLP challenge (Figures 7a and b) . In contrast, the lungs of pCAGGS-vaccinated mice at the same time point exhibited diffuse pulmonary edema, alveolar wall thickening and extravasation of an inflammatory infiltrate and red blood cells into the interstitium (Figures 7d and e). The lungs of MIF/TTX DNA-or pCAGGSvaccinated mice were normal at 12 h after sham operation, that is, intraperitoneal (i.p.) injection of 200 ml of saline (Figures 7c and f) . Thus, MIF/TTX DNA vaccination attenuated the acute lung injury that occurs after septic shock.
Effect of MIF/TTX DNA vaccination on the wound healing of the skin
We observed that the reparative pattern was characterized by formation of a dehydrated wound crust, gradual loss of the lesion surface, appearance of a thin residual skin defect, closure of the wound surface and reappearance of the epithelial surface. We examined the appearance of round skin wounds of the mice that had received either MIF/TTX DNA or pCAGGS vaccination to assess the effect of this approach on the wound healing process. Complete healing was seen between 8 and 15 days after the surgery for the pCAGGS-vaccinated mice whereas the MIF/TTX DNA-vaccinated mice showed a slight delay of healing, that is, between 9 and 16 days ( Figure 8) . The difference was not statistically significant between the groups. 
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Long-term effects of MIF/TTX DNA vaccination on mortality, whole body/organ weights, levels of serum/urine markers and anti-MIF Ab titer in mice Concerning mice that had passed 18 months after vaccination with MIF/TTX DNA or pCAGGS, we investigated their survival rates, the body weights, the organ weights (lung, liver and kidney), the levels of serum markers (glutamic-oxaloacetic transaminase (GOT), glutamic-pyruvic transaminase (GPT) and creatinine), urinary protein levels and the levels of anti-MIF antibody titers. As shown in Table 1 , all the mice survived irrespective of the treatment, and there were no statistical difference between the groups concerning the body and organ weights, the levels of serum markers and urinary protein levels. As for the levels of anti-MIF antibody titers, there was no statistical difference between the groups, though the level seemed to be higher in MIF/TTX DNA vaccine group. Namely, it was suggested that the significant enhancement of serum levels of anti-MIF antibody titer did not last over a long period of time, and that no lethal complications that accompany MIF/TTX DNA vaccination were expected.
Discussion
In the current study, we showed that active immunization against MIF may be a novel approach for the prophylaxis of sepsis and potentially other inflammatory diseases as well. Although the pathogenesis of sepsis has been attributed to dysregulated systemic inflammatory responses characterized by excessive accumulation of various proinflammatory mediators such as TNF, IL-6, 10 IL-1, 11 interferon-g, 12 nitric oxide 13 and MIF, 14, 15 we focused on MIF as a prophylactic target for sepsis for the following reasons. First, MIF is believed to be located upstream of TNF within the cytokine cascade, as MIF upregulates the production of TNF-a by macrophages 16 and MIF-deficient mice generate lower amounts of inflammatory cytokines like TNF-a in response to LPS stimulation. 17 Second, the usefulness of MIF as a target in sepsis therapy has been highlighted by the ability of neutralizing anti-MIF antibodies to protect mice from lethal endotoxemia. 3, 18 Although Honma et al. 19 showed no significant difference between WT and MIF-deficient mice in the survival rate after i.p. injection of LPS and concluded that MIF is not crucial for LPS-induced immune responses leading to lethal shock, numerous subsequent reports have suggested that MIF is implicated in the pathogenesis of sepsis and that MIF-directed therapies might offer new treatment opportunities for sepsis. 20 Thus, it is reasonable to propose that suppressing MIF activity may be more effective way of treating sepsis than suppressing other inflammatory cytokines.
In our current study, prophylactic MIF/TTX DNA vaccination significantly reduced mortality in two different murine models of sepsis. These models differ in their pathophysiology. We were quite confident that 
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targeting MIF by active immunization would prevent sepsis in the LPS model given that MIF is indispensable for the intracellular transduction of LPS signaling by TLR4, the signal-transducing molecule of the LPS receptor complex. 5 However, LPS does not appear to be a major contributor to sepsis-induced mortality in the CLP models because genetic ablation of TLR4, the most important LPS receptor, failed to improve the survival of mice challenged with CLP. 21 In addition, the circulating LPS levels were found to be very low in the CLP model. 22 Echtenacher et al. 21 have suggested that CLP initiates a more complex immunological response than that resulting from LPS or infection with a single bacterial species; this makes this model more clinically relevant than the LPS model. Despite these differences from the LPS model, our vaccine against MIF protected mice from CLP-induced mortality as well. This is consistent with previous observations showing that neutralization or suppression of MIF bioactivity prevents CLP-induced mortality. 3, 23 Thus, our approach is likely to be effective for the prevention of clinical sepsis.
Sepsis induces multiple organ failure, including ARDS, which is a terminal stage of acute lung injury. MIF has been suggested to play a critical role in mediating the inflammatory lung injury in ARDS as the alveolar airspaces of ARDS patients contain high levels of MIF. 24 However, how MIF contributes to alveolar inflammation remains unclear. 4 We hypothesized that the pathophysiological lung inflammation events that lead to ARDS were due to the enhancement of the cytokine cascade that is triggered by released MIF. To test this, we examined the effect of MIF/TTX DNA vaccination on the mRNA levels of inflammatory cytokines in the lung tissues of mice with sepsis. As neutralization of MIF was reported to be associated with decreased mRNA expressions of IL-1b and IL-6 in LPS-induced rat myocardial dysfunction model, 25 mRNA levels of these proinflammatory cytokines were also measured. We found that MIF/TTX DNA vaccination suppressed TNF, IL-1b and IL-6 expression in the lung upon challenge with LPS or CLP. We also measured the mRNA levels of MIP-2 because the acute injury model is characterized by a pulmonary inflammatory response associated with neutrophil infiltration and early rises in the levels of proinflammatory cytokines such as TNF-a, IL-1b, IL-6 and MIP-2. 16 MIF/TTX DNA vaccination also significantly suppressed MIP-2 expression in lung tissues after onset of sepsis. Moreover, we measured the mRNA levels of TLR-4, which plays a pivotal role in innate immunity as a receptor for LPS, in the lung tissues. The levels were significantly lower in MIF/TTX group at approximately 6 h after LPS or CLP challenge. We speculate that this suppression may be caused by overall suppression of the inflammatory cytokine network, as the expression of TLR-4 is reported to be positively regulated by inflammatory cytokines such as IL-1b and TNF-a. 26 It could also be supposed that this suppression of TLR-4 expression has led to LPS sensitivity, resulting in lower mortality after LPS challenge. These data support our finding that MIF/TTX DNA vaccination suppresses mortality after septic shock.
DNA vaccination is a novel immunization technique that has been used against a variety of pathogens, cytokines and tumors. 27 DNA vaccines allow us to express antigens in vivo in such a way that both humoral and cell-mediated immune responses can be evoked simultaneously. DNA vaccines also do not bear the safety risks associated with live vaccines. As a result, compared to conventional vaccines, DNA vaccines have far greater potential in helping prevent and treat fatal diseases and infections. 28 Indeed, the efficacy of DNA vaccines in preclinical animal models is now well documented. 29 DNA vaccines also have the advantage over recombinant protein vaccines in that the construction and purification of vectors for DNA vaccination is relatively simple. This approach is thus likely to increase the speed and decrease the effort required to develop novel protein vaccines. Moreover, this approach is useful for rapidly screening potential protein immunogens.
We showed here that active immunization with the MIF/TTX DNA vaccine attenuated sepsis-related inflammation. If this approach could be clinically applicable to humans, it would be useful for people who are at Figure 8 Effects of macrophage migration inhibitory (MIF)/ tetanus toxin (TTX) DNA vaccination on healing of skin wound lesions. The number of mice with complete healing of skin lesion was plotted at different time points after penetrating wounds through both the epidermis and dermis (MIF/TTX DNA-vaccinated mice, n ¼ 10; pCAGGS-vaccinated mice, n ¼ 10). Table 1 Long-term effects of MIF/TTX DNA vaccination on mortality, whole body/organ weights, levels of serum/urine markers and anti-MIF Ab titer in mice 0.151 ± 0.046 0.245 ± 0.126 NS Abbreviations: Ab, antibody; GOT, glutamic-oxaloacetic transaminase; GPT, glutamic-pyruvic transaminase; MIF, migration inhibitory factor; NS, not significant; TTX, tetanus toxin.
MIF/TTX DNA vaccination and sepsis S Tohyama et al relatively high risk of suffering trauma or burns (for example, firefighters and policemen), although the Ab response elicited by the vaccine would have to be longlived in such cases. Patients awaiting complicated surgery would also be suitable for prophylactic vaccination against post-surgical infection and subsequent sepsis. In this case, the vaccine regimen would have to elicit the anti-MIF autoantibodies relatively quickly. The vaccine may also be useful as an adjunct to anti-MIF Abs in treating patients with unexpected acute injuries such as burns and trauma. In this case, the anti-MIF Abs would hold sepsis at bay until the vaccine has enough time to elicit anti-MIF autoantibodies, which would then prevent the procrastination or relapse of infection-driven inflammation.
Concerning the predicted problems that might arise from continuous suppression of MIF bioactivity, it should be noted that the presence of autoantibody against cytokines is not necessarily harmful. Indeed, it could be protective against diseases, as exemplified by the finding of Jouvenne et al. 30 , who reported that the titer of autoantibodies to IL-1b correlated negatively with the disease severity of chronic arthritis. Moreover, previous reports of active immunization against cytokines have revealed that the autoantibody titer tends to gradually decrease over time. Thus, it is unlikely that a single administration of such a vaccine is irreversible. 31 Rather, to acquire and maintain high autoantibody titers, it may be necessary to provide booster injections or revaccination. 32 In this study, we performed preliminary safety studies. We examined the wound healing ability of mice at 6 weeks after vaccination, and found no statistical difference between MIF/TTX group and control group. Abe et al. 33 previously reported that the administration of anti-MIF antibody resulted in significantly delayed wound healing in C57BL6 mice; however, we failed to show such significant difference, although MIF/TTX group tended to show slight delay in wound healing. Concerning this discrepancy, it is known that the wound healing ability of mice are influenced by their strain, and BALB/c mice generally tend to show delayed wound healing compared with C57BL6. Therefore, we speculate that the discrepancy between Abe's results and ours might in part be caused by the different genetic background of the mice used. Another explanation may be that the effect of polyclonal anti-MIF autoantibodies elicited by vaccination on the wound healing may be different form that of passively administered neutralizing anti-MIF monoclonal antibody that Abe et al. used in their study. Moreover, concerning mice that had passed 18 months after vaccination with MIF/TTX DNA or pCAGGS, we examined their mortality, whole/organ weight and serological markers for liver/renal functions, all of which showed no statistical difference between the two groups. Taken together, we have so far found no evidence that suggests any deadly side effects that accompany our novel approach.
Recent studies have demonstrated that various inflammation-related proteins may be promising targets for sepsis therapies. These include HMBG-1, A 2A and C5a. [34] [35] [36] Our results confirm that MIF is also a promising target for the treatment of sepsis. We also show that MIF/TTX DNA vaccination may provide a new strategy for the prevention and management of sepsis.
Materials and methods
Mice BALB/c mice (3-week-old) were purchased from Sankyo Lab (Shizuoka, Japan) and maintained under specific pathogen-free conditions. All mice were kept on a 12:12 h light-dark cycle with free access to food and water. All animal procedures were conducted under an approved protocol according to the guidelines of the Hokkaido University Institutional Animal Care and Use Committee.
MIF/TTX DNA vaccination
We previously reported the design of the MIF/TTX DNA expression plasmid and our analysis of the in vitro expression of MIF/TTX by this plasmid. 7 Gene transfer into muscle was performed by in vivo electroporation essentially as described previously. 37 Briefly, 4-week-old mice were anesthetized with ether and shaved around their hind legs, after which a pair of electrode needles (5 mm gap and 0.5 mm diameter, NEPA GENE, Chiba, Japan) was inserted into an anterior tibial muscle and the DNA vaccine (25 mg/25 ml 0.9% saline) or control pCAGGS plasmid (25 mg/25 ml 0.9% saline) was injected into the portion between the needles. Three electric pulses of 50 V for 50 ms were applied by using an electric pulse generation system (T820 and Optimizer 500, BTX, San Diego, CA, USA) and were followed by another three pulses with inverted polarity. The other tibial muscle was then also injected and electroporated. As a result, each mouse received 50 mg of the naked plasmid.
Evaluation of anti-MIF Ab titers in the plasma of DNA-vaccinated mice
Anti-MIF titers in the plasma were determined by a direct enzyme-linked immunosorbent assay (ELISA). Briefly, individual plasmas from vaccinated mice were collected from the tail vein and diluted with 0.1% bovine serum albumin (BSA)/phosphate-buffered saline (PBS)/ 0.05% Tween 20. Small aliquots of diluted plasma (1:200) were placed into 96-well flat-bottom plates precoated with recombinant mMIF. The serum anti-MIF antibodies that reacted with the precoated MIF were detected by incubation with a horseradish peroxidase (HRP)-conjugated goat anti-mouse Ab followed by color development with a substrate reagent (Techne, Minneapolis, MN, USA).
Animal models Lipopolysaccharide model. BALB/c mice that had been vaccinated with MIF/TTX DNA or pCAGGS were injected i.p. 6-7 weeks later with 15 mg kg À1 LPS (Escherichia coli O111:B4; SigmaAldrich, St Louis, MO, USA) dissolved in pathogen-free saline solution. The mice were observed at least twice a day and mortality over the 3 days after LPS injection was recorded.
Cecal ligation and puncture model. BALB/c mice that had been vaccinated with MIF/TTX DNA or pCAGGS were anesthetized 6-7 weeks later with pentobarbiturate (0.15 ml/10 g, i.p, Dainippon-Sumitomo Pharma, Tokyo, Japan) and an abdominal midline incision was made under sterile conditions. The cecum was then exposed, ligated at about 40% of its length with a 4-0 suture, and punctured twice with an 18-gauge needle. Finally, the ) or subjected to CLP. Blood samples were then collected by heart puncture at 0, 2, 6, 12 and 24 h (LPS model and CLP model). We also checked serum levels of IL-1b, IL-6, MIP-2 and MIF. The serum concentrations of TNF-a, IL-1b and IL-6 were measured using an ELISA kit for mouse TNF-a, IL-1b and IL-6 (Biosource, Camarillo, CA, USA), according to the manufacturer's protocol. The serum concentrations of MIP-2 were measured using a mouse MIP-2 ELISA kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's protocol. The mouse MIF ELISA followed a previously reported sandwich method 38 and employed immobilized rabbit anti-mouse MIF polyclonal antibodies, 0.1% BSA in PBS as blocking agent, and a HRP-conjugated mouse anti-MIF monoclonal antibody (3-3G8B) as detector. The detection limit was 1.6 ng ml
À1
.
RNA extraction and quantitative real-time PCR
Lung tissues were harvested and total RNA was extracted with TRIzol (Ambion, Foster City, CA, USA) according to the manufacturer's protocol. Real-time PCR was performed as previously described. 39 Primers were obtained from the Perfect Real-Time support system (Takara Bio, Tokyo, Japan) and their respective forward and reverse sequences are as follows. Reverse transcription reactions were performed with PrimeScript (Takara Bio, Tokyo, Japan) and 100-500 ng total RNA according to the manufacturer's protocol. The relative quantitation method (DDcycle threshold) 40 was used to evaluate the expression of the selected genes using the b-actin as an internal control and the normalizer for all data. All PCR assays were performed five times.
Histopathology
MIF/TTX-DNA or pCAGGS-vaccinated mice were killed under anesthesia 12 h after LPS challenge, CLP challenge or sham operation, that is, i.p. injection of 200 ml of saline. The whole lung was harvested, fixed in 4% paraformaldehyde in PBS and then embedded in paraffin. Serial sagittal sections were subjected to hematoxylin and eosin staining for histological analyses.
Wound healing experiments
For wound healing experiments, mice (BALB/c, female 10 weeks) that had received either MIF/TTX DNA or pCAGGS vaccination at 4 weeks were anesthetized with sodium pentobarbital solution (0.15 ml/10 g, i.p. Dainippon-Sumitomo Pharma, Tokyo, Japan) and their dorsal hair was clipped. One penetrating wound through both the epidermis and dermis were prepared on the upper back of each mouse using a punch biopsy instrument (8 mm diameter). The wounds were left open during the experiments. We examined the appearance of the skin wound lesions until the epithelial surface was restored.
Long-term effects of MIF/TTX DNA vaccination on mortality, body/organ weights, levels of serum/urine markers, and anti-MIF Ab titer in mice At 18 months after vaccinating 4-week-old BALB/c mice with MIF/TTX DNA (n ¼ 9) or pCAGGS (n ¼ 8), we counted their survival rates. After killing, the weights of whole body, lung, liver and kidney of the mice were evaluated. Blood and urine samples were also collected, and the levels of serum GOT, GPT, creatinine and urinary protein were measured. For the measurements, we used Sikarikit AST (Kanto Chemical, Tokyo, Japan) for murine GOT, Sikarikit ALT (Kanto Chemical) for murine GPT, Pureauto S (Sekisui medical, Tokyo, Japan) for murine creatinine, and Micro TP-test (Wako Pure Chemical, Tokyo, Japan) for murine urinary protein, according to the manufacturer's protocols.
Statistical analysis
The data are expressed as means ± s.e.m. The differences among groups were analyzed by Mann-Whitney U-test, or one-way analysis of variance using Fisher's test as a post hoc test. Kaplan-Meier survival curves were analyzed by using the log-rank test. Values of Po0.05 were considered significant.
